Health
InventisBio Announces Positive Phase 2 Study Results for D-2570 (TYK2 Inhibitor) in Patients with Moderate to Severe Plaque Psoriasis
– D-2570 demonstrates robust efficacy and favorable safety profile, achieving skin clearance comparable to leading biologics – SHANGHAI, Dec. 3, 2024 /PRNewswire/ -- InventisBio Co., Ltd. today announced promising results from a Phase 2 clinical tria
By: en_prnasisa
- Dec 03 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS
Share this page
Guest Posts by Easy Branches in Patients with Moderate to Severe Plaque Psoriasis&url=https://easybranches.com/feed/hk/health/10654658&media=https://easybranches.com/feed/assets/images/default.png){kind=link}
